About KLISBio
KLISBio is a company based in Bresso (Italy) founded in 2013 by Antonio Alessandrino and Gabriele Grecchi. KLISBio has raised $8.58 million across 8 funding rounds from investors including European Union, ComoNExT and Principia SGR. KLISBio offers products and services including Nerve Repair Implant, Bone Grafting Material, Tendons and Ligaments Repair Product, and Vascular Graft. KLISBio operates in a competitive market with competitors including Checkerspot, Fermbox, Bcomp, Industrial Microbes and FibroHeal, among others.
- Headquarter Bresso, Italy
- Founders Antonio Alessandrino, Gabriele Grecchi
-
Sectors
HealthcareChemicals & Materials Technology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Klisbio S.R.L.
-
Annual Revenue
Not available
-
Net Profit
-$432.15 K (USD)44as on Dec 31, 2023
-
EBITDA
-$432.15 K (USD)44as on Dec 31, 2023
-
Total Equity Funding
$8.58 M (USD)
in 8 rounds
-
Latest Funding Round
$7.94 M (USD), Series A
Apr 21, 2016
-
Investors
European Union
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of KLISBio
KLISBio offers a comprehensive portfolio of products and services, including Nerve Repair Implant, Bone Grafting Material, Tendons and Ligaments Repair Product, and Vascular Graft.
Implant for repairing nerves using silk fibroin material.
Material for promoting bone regeneration in surgical procedures.
Product for repairing soft tissues like tendons and ligaments.
Graft for vascular applications to support tissue regeneration.
People of KLISBio
Unlock access to complete
Unlock access to complete
Funding Insights of KLISBio
KLISBio has successfully raised a total of $8.58M across 8 strategic funding rounds. The most recent funding activity was a Series A round of $7.94 million completed in April 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in KLISBio
KLISBio has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, ComoNExT and Principia SGR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments in Italian tech and life sciences are targeted.
|
Locked | Locked | Locked | |
|
Business incubation and acceleration for exponential technologies are provided.
|
Locked | Locked | Locked | |
|
Startup incubation for SMEs is facilitated by ComoNExT.
|
Locked | Locked | Locked |
Investor details for KLISBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by KLISBio
Investment portfolio details for KLISBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - KLISBio
Detailed financials for KLISBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Klisbio Comparisons
Peer comparison for KLISBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of KLISBio
KLISBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Checkerspot, Fermbox, Bcomp, Industrial Microbes and FibroHeal, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
High-performance materials are developed using synthetic biology for diverse applications.
|
|
| Locked | Locked | Locked |
Alternative animal products are developed via microbial precision fermentation.
|
|
| Locked | Locked | Locked |
Sustainable biomaterials for lightweighting in automotive and aerospace are provided.
|
|
| Locked | Locked | Locked |
Developer of fermentation technology to convert methane and carbon dioxide into useful chemicals
|
|
| Locked | Locked | Locked |
Developer of silk proteins as biomaterials for wound healing
|
|
| Locked | Locked | Locked |
Engineering agri-waste into purpose
|
Detailed competitors of KLISBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Klisbio
Frequently Asked Questions about KLISBio
KLISBio was founded in 2013.
KLISBio is headquartered in Bresso, Italy. It is registered at Bresso, Lombardy, Italy.
Gabriele Grecchi is the current CEO of KLISBio. They have also founded this company.
KLISBio is a funded company, having raised a total of $8.58M across 8 funding rounds to date.
KLISBio was founded in 2013 in Bresso, Italy, within the biotechnology sector focused on regenerative medicine. A silk-based technology platform is employed to create scaffold materials addressing peripheral nerve injuries, vascular diseases, bone defects, tendon tears, and needs for sustained drug release. Operations center on developing implantable products for these indications, with research and development conducted from the companys Italian base.
KLISBio's top competitors include Checkerspot, FibroHeal and Bloom Biorenewables.
KLISBio offers Nerve Repair Implant, Bone Grafting Material, Tendons and Ligaments Repair Product, and Vascular Graft.
KLISBio has 6 investors. Key investors include European Union, ComoNExT, Principia SGR, Singularity, and PNICube.